Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety
This meta-analysis suggests that JAKi treatment of MPN was associated with a reduced risk of thromboembolic events; primarily driven by studies of ruxolitinib in PV and MF. Further prospective clinical trials are warranted to confirm these findings and characterise the cardiovascular profile of other JAKis and other types of MPNs.
Authors
- Jennifer O’Sullivan (ORCID: https://orcid.org/0000-0003-0502-7133)
- Edouard Long (ORCID: https://orcid.org/0009-0002-1008-7966)
- Claire N. Harrison (ORCID: https://orcid.org/0000-0002-3212-920X)
- Yunfan Yang (ORCID: https://orcid.org/0000-0002-2924-7002)
- Roberta Dunn (ORCID: https://orcid.org/0009-0003-7253-9128)
- L. Gagnon (ORCID: https://orcid.org/0009-0002-3764-7628)
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- King's College School (GB)
- Université Laval (CA)
Publication Details
- Journal
- eJHaem
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/jha2.70000
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63